Overview

Tc99m Sestamibi Molecular Breast Imaging

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
0
Participant gender:
Female
Summary
The goal of this clinical research study is to compare Tc99m sestamibi molecular breast imaging (MBI) scans to mammograms and ultrasounds (the current standard of care) to learn if MBI scans can measure if the disease is responding to chemotherapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Technetium Tc 99m Sestamibi
Criteria
Inclusion Criteria:

1. Female of 18 years and older of any race

2. Has biopsy-proven invasive breast cancer (BI-RADS 6) and scheduled for neoadjuvant
chemotherapy (NAC).

3. Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson
Cancer Center, or referred to MD Anderson for treatment after initial radiologic
(mammographic, sonographic, etc.) exams at an outside institution in whom NAC is
planned.

4. Patients with stage T1 or greater (T1-T4), nodal involvement (N0 - N3), without
metastasis (M0) invasive breast cancer, including patients with inflammatory breast
cancer.

5. Patients who agree to sign an informed consent to undergo MBI

Exclusion Criteria:

1. Is under 18 years of age

2. Is pregnant (confirmed by the patient as Imaging Clinic standard of care) or nursing
mother

3. Has lesions involving chest wall

4. Has known allergy to Tc99m sestamibi